Cristina Cusin MD
Director of Translational Studies in Depression at Massachuseets General Hospital. Assistant Professor in Psychiatry at Harvard Medical School.
Join to View Full Profile
101 Nicolls RdBoston, MA 11794
Phone+1 617-726-2066
Dr. Cusin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 2006 - 2010
University of Milan Faculty of MedicineClass of 1997
Certifications & Licensure
MA State Medical License 2009 - 2026
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression Start of enrollment: 2010 Nov 01
- Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression Start of enrollment: 2012 Apr 01
- Neurobiological Bases of Placebo Response in Major Depressive Disorder Start of enrollment: 2012 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Exploring Task Design and Heuristics Interaction Through a Knowledge-Free Option Generation Task.Yanlin Chen, Yuen-Siang Ang, Cristina Cusin, Maurizio Fava, Diego A Pizzagalli
Scandinavian Journal of Psychology. 2025-04-01 - Novel multi-modal methodology to investigate placebo response in major depressive disorder.Cristina Cusin, Daniel G Dillon, Emily Belleau, Marc D Normandin, Yoann Petibon
Journal of Affective Disorders. 2025-01-01 - 3 citationsEffects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-c...A John Rush, Charles R Conway, Scott T Aaronson, Mark S George, Patricio Riva-Posse
Brain Stimulation. 2024-12-18
Journal Articles
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
Press Mentions
Ketamine Derivative OK’d by FDA Can Be a Wonder Drug for Some. Insurers Still Have to Catch UpFebruary 24th, 2025- Atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine TreatmentNovember 17th, 2022
- Placebo Effect Large in Treatment-Resistant DepressionSeptember 30th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
